Advertisement
CEL-SCI Corporation develops immune-based cancer and infectious diseasetherapies. Its primary product candidate is Multikine(R), a next-generation,comprehensive immunotherapy that targets treatment-naive, newly diagnosed headand neck cancer. Multikine(R) is a mixture of biologically active naturalcytokines designed to closely mimic the natural immune system.
Advertisement
Differing from other immunotherapies, Multikine(R) has the followingattributes: (1) multitargeted-it activates multiple cellular components of theimmune system to fight cancer; (2) administered as a first-line therapy beforethe patient receives surgery, chemotherapy, or radiotherapy, which is when theimmune system is strongest; (3) kills roughly 50% of tumor cells before thestandard of care is begun; (4) renders the residual live cancer cells thatsurvive treatment more susceptible to the effects of radiation andchemotherapy, thereby potentially enhancing these treatments; and (5) is shownto be safe and well tolerated in Phase I and II clinical trials. In over 200patients treated in CEL-SCI's trials, no severe side effects associated withMultikine(R) were reported.
Multikine(R) is now ready for a Phase III clinical trial for advancedprimary head and neck cancer. In Phase III, CEL-SCI intends to administerMultikine(R) prior to the currently accepted and routinely used first-linestandard of care treatment-surgery followed by radiation/chemotherapy. TheCompany hopes to show that Multikine(R) plus the standard of care increasespatients' overall survival. CEL-SCI believes that a positive Phase III outcomecould enable Multikine(R) to be routinely included as part of the standard ofcare for all advanced primary head and neck cancer patients. Multikine(R) mayalso have applications in melanoma and breast, skin, bladder, and cervicalcancer.
Also in CEL-SCI's pipeline are two other platforms, a Ligand EpitopeAntigen Presentation System (L.E.A.P.S.)(TM) and Antigen-Directed Apoptosis(AdapT), with a second product candidate, CEL-1000. CEL-1000, derived fromL.E.A.P.S.(TM), is poised for trials as a potential adjuvant to boost vaccineimmunogenicity for viral encephalitis, herpes simplex, malaria, hepatitis B,and the avian flu.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm thatprovides institutional-quality, fee-based research to small and mid-capcompanies. Crystal Research Associates' unique and novel product, theExecutive Informational Overview(R) (EIO(R)), is free of investment ratings,target prices, and forward-looking financial models. The EIO(R) presents acrystal clear, detailed report on a company (public or private) in a mannerthat is easily understood by the Wall Street financial community. The EIO(R)details a company's product/technology/service offerings, market size(s), keyintellectual property, leadership, growth strategy, competition, risks,audited financial statements, key events, and other such fundamentalinformation. Crystal Research Associates has offices in New York City, DelrayBeach, Montreal, and Toronto. Crystal Research Associates has been compensatedby the Company in cash of thirty-five thousand U.S. dollars and two hundredthousand options/warrants to purchase CEL-SCI stock for its services increating the base report, for updates, and for printing.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operatingresults, potential applications of the Company's technology, opportunities forthe Company, and any other statements about the future expectations, beliefs,goals, plans, or prospects expressed constitute forwa
